Literature DB >> 27396594

The Influence of Tetracycline Inducible Targeting Rat PPARγ Gene Silencing on the Osteogenic and Adipogenic Differentiation of Bone Marrow Stromal Cells.

Xiaobo Feng, Xianzhe Liu, Xianyi Cai, Tao Lin, Weihua Xu, Cao Yang, Yongwei Liu, Shuhua Yang, Dehao Fu1.   

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) has been considered as the master regulator for adipogenesis of bone marrow stromal cells (BMSCs). However, there are few reports regarding the effect of PPARγ gene silencing on osteogenic and adipogenic differentiation in rat BMSCs, and no reports about tissue targeting and conditional knockdown of PPARγ gene. In this study, we construct rat PPARγ gene shRNA Tet-on lentiviral vector, the lentiviral vector facilitated tetracycline (which has the characteristics of bone targeting)-inducible knockdown specific to PPARγ gene, and transfect it into BMSCs, the silencing effects induced by tetracycline is significant. The expression of the adipogenic factors adipocyte determination and differentiation-dependent factor 1 (ADD1) and recombinant CCAAT/enhancer binding protein alpha (C/EBPα) were decreased as measured by RT-PCR and Western blot assay following PPARγ silencing. In contrast, expression of the osteogenic genes encoding collagen I and Cbfa1/Runx2 were increased. In adipogenic medium, PPARγ-shRNA transfection reduced the lipid droplet count as measured by Oil red O staining when compared to the control groups. In osteogenic medium, PPARγ-shRNA increased the activity of alkaline phosphatase and the amount of calcium deposition as measured by Alizarin red S staining. These results suggest that the rat PPARγ gene shRNA Teton lentiviral vector decreases adipogenic differentiation and promotes osteogenic differentiation in BMSCs induced by tetracycline. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Adipogenic differentiation; Osteogenic differentiation; PPARγ; Rat bone marrow stromalzzm321990cells; Tetracycline; lentiviral vector; shRNA

Mesh:

Substances:

Year:  2016        PMID: 27396594     DOI: 10.2174/1381612822666160708223353

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  1 in total

Review 1.  Development of Bone Targeting Drugs.

Authors:  Molly Stapleton; Kazuki Sawamoto; Carlos J Alméciga-Díaz; William G Mackenzie; Robert W Mason; Tadao Orii; Shunji Tomatsu
Journal:  Int J Mol Sci       Date:  2017-06-23       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.